GoodRx (Foundayo + Zepbound KwikPen) vs RNK Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
RNK Health
Best for compounded GLP-1 buyers also interested in NAD+, peptide, or longevity add-ons in the same provider relationshipStarting at $197/mo
Side-by-Side Comparison
| Feature | GoodRx (Foundayo + Zepbound KwikPen) | RNK Health |
|---|---|---|
| Overall Score | ✓8.4/10 | 7.3/10 |
| Starting Price | ✓$149/mo | $197/mo |
| Editorial Rating | ✓4.2 ★ /5 | 3.7 ★ /5 |
| Features | ✓6 features | 5 features |
| States Available | ✓50 | 0 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
RNK Health
Pros
- ✓Both injectable and oral compounded semaglutide formats — wider format optionality than most stub entries in the cluster
- ✓GLP-1 + longevity stack (NAD+, sermorelin, enclomiphene, DNA testing) lets one provider serve readers also interested in performance/longevity adjacencies
- ✓Pricing is publicly displayed — $297/mo tirzepatide, $197/mo injectable semaglutide, $198/mo oral semaglutide
Cons
- ✗States served not enumerated on the public landing page — needs direct confirmation before any state-page placement
- ✗Pharmacy partner not publicly named beyond a Springville, UT fulfillment reference
- ✗Compounded only on the GLP-1 side — no FDA-approved Wegovy/Zepbound brand-name option
Our Verdict
GoodRx (Foundayo + Zepbound KwikPen) edges out RNK Health with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. RNK Health remains a solid alternative, especially if you're looking for compounded GLP-1 buyers also interested in NAD+, peptide, or longevity add-ons in the same provider relationship.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.